Polaryx Therapeutics (PLYX)

Executive Summary

Polaryx Therapeutics (NASDAQ: PLYX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare pediatric neurodegenerative diseases, specifically lysosomal storage disorders. Its sole drug candidate, PLX-200, is an orally administered small molecule designed to induce autophagy and reduce toxic accumulation in neurons. PLX-200 is being investigated for CLN2 (Late-Infantile Neuronal Ceroid Lipofuscinosis) and CLN3 (Juvenile Neuronal Ceroid Lipofuscinosis), both fatal genetic disorders with no approved treatments. The company is currently conducting a Phase 3 trial (NCT04637282) for CLN3, which began recruiting in March 2026. With a market cap of ~$244 million, Polaryx represents a high-risk, high-reward opportunity in the rare disease space. The upcoming data readout from this pivotal trial is a critical catalyst for the company's valuation and potential regulatory path.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data for PLX-200 in CLN3 (Juvenile NCL)60% success
• Q4 2026Initiation of Phase 2/3 Trial for PLX-200 in CLN2 (Late-Infantile NCL)40% success
• Q2 2026FDA Regulatory Guidance or Fast Track Designation Update70% success